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Introduction: Uveal melanoma (UM) is the most common primary intraocular malignancy 
with very poor prognosis. Conventional chemotherapy only rarely prolongs the survival, 
therefore patients require novel treatment modalities. The discovery of specific receptors for 
hypothalamic hormones on cancer cells has led to the development of radiolabeled and cyto-
toxic hormone analogs.
Materials and methods: In the present study, our aim was to investigate the expression of mRNA 
for receptors of luteinizing hormone-releasing hormone type I (LH-RH-I) and LH-RH ligand in 
OCM-1 and OCM-3 human uveal melanoma cell lines. The presence and binding characteristics of 
LH-RH-I receptor protein was further studied by Western blot, immunocytochemistry and ligand 
competition assay. The expression of mRNA and protein for LH-RH-I receptors has been also stud-
ied using tumor samples originating from nude mice xenografted with OCM-1 or OCM-3 cells.
Results: The mRNA for LH-RH-I receptor has been detected in OCM-1 and OCM-3 cell lines 
and was found markedly higher in OCM-3 cells. The mRNA for LH-RH-I receptors was also 
observed in both UM xenograft models in vivo with higher levels in OCM-3. The presence of 
LH-RH-I receptor protein was found in both cell lines in vitro by immunocytochemistry and 
Western blot, and also in tumor tissue samples grown in nude mice by Western blot. Both human 
uveal melanoma models investigated showed specific high affinity receptors for LH-RH-I using 
ligand competition assay. The mRNA for LH-RH ligand has also been detected in OCM-1 and 
OCM-3 cell lines and cancer tissues.
Conclusion: The demonstration of the expression of LH-RH-I receptors in OCM-1 and OCM-3 
human UM cell lines suggests that they could serve as potential molecular target for therapy. Our 
findings support the development of new therapeutic approaches based on cytotoxic LH-RH ana-
logs or modern powerful antagonistic analogs of LH-RH targeting LH-RH-I receptors in UM. 
Keywords: human uveal melanoma, LH-RH receptor, LH-RH ligand, targeted cancer therapy
Introduction
Uveal melanoma (UM) is an intraocular melanoma arising from melanocytes of the 
uveal tract, which is composed of the choroidea, ciliary body (CB), and iris.1 UM is the 
most common intraocular tumor and its prognosis depends on the size of the primary 
tumor, the time of diagnosis, and the presence of metastases.2 A number of clinical 
and histological risk factors have been defined over the last three decades, among 
others – clinicopathological factors like location, extraocular growth, involvement of 
the CB, and the epitheloid cell type of the tumor.3 Larger tumors are associated with 
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a mortality rate of ~50% shortly after the diagnosis, while 
patients with medium-sized tumors show 50% survival rate 
over 15 years measured from primary tumor treatment.2 
Nearly 50% of patients suffering from UM develop metastatic 
disease, that usually involves the liver and is almost inevi-
tably fatal.4 When metastases develop, the median survival 
of the patients is only 5–7 months.5 
Primary tumors are treated either by brachytherapy 
using radioactive plaques to preserve the tissues of the eye 
or by enucleation.6 Treatment by chemotherapy only rarely 
prolongs survival and new treatment modalities are needed.7 
Two distinct classes of UMs have been identified by its gene 
expression profile.8 Class I tumors exhibit low aneuploidy, 
and patients rarely have metastases, whereas class II tumors 
have a higher chance of aneuploidy and patients have a high 
risk to develop metastases.9 Monosomy 3 strongly relates 
to several clinical and histopathological parameters such 
as epithelioid cells, closed vascular patterns, large tumor 
diameter, and CB involvement.10 Several groups have already 
shown that there is a strong correlation between monosomy 3 
and the development of metastatic diseases.10,11 Lack of chro-
mosome 3 has been demonstrated in 5%–10% of all the 
patients and the remaining copy is duplicated.12 Monosomy 3 
is present in 50%–60% of UM tumors, and is associated with 
isochromosome 8q and high level of 8q gain.9 In our previ-
ous study, we demonstrated aneuploidy of chromosome 4 in 
70% of human UM specimens.13 Furthermore, a correlation 
was found between the copy number of chromosome 3 and 
4 and the survival of patients.13 BRCA1-associated protein 1 
(BAP1) is located on chromosome 3p21.1 and is thought to 
be a tumor suppressor gene.14 Inactivating somatic mutations 
were found in 84% of the metastasizing UMs, implicating 
that BAP1 mutations occur late in the UM progression.14 
Recently, several candidate genes have been proposed in 
UM; LZTS1, GNAQ, DDEF1, NBS1, HDM2, BCL-2, and 
CCND1, among others. For most of these genes, a definite 
role in tumorigenesis or progression toward metastasis is still 
yet to be validated.15,16
The discovery of specific receptors for hypothalamic 
hormones on cancer cells has led to the development 
of radiolabeled and cytotoxic hormone analogs. These 
analogs are more selective in wiping out cancer cells and 
less toxic than conventional chemotherapeutic agents.17–20 
Hypothalamic luteinizing hormone-releasing hormone 
(LH-RH) is the primary regulator of gonadal function and 
plays a pivotal role in vertebrate reproduction.18–20 The 
actions of LH-RH are mediated by specific G protein-cou-
pled receptors (GPCRs) for LH-RH present on the plasma 
membranes of the pituitary gonadotrophs.19,20 Those specific 
membrane receptors for LH-RH have been found in various 
animal and human cancers and can mediate direct effects 
of LH-RH agonists, antagonists, and cytotoxic LH-RH 
conjugates.18–21 Receptors for LH-RH have been demon-
strated on breast, prostate, ovarian, endometrial cancers, 
melanomas, and renal cell and colorectal carcinomas.18–26 
Previously, we have also demonstrated the expression of 
LH-RH ligand and LH-RH type I (LH-RH-I) receptors in 
human UM specimens.27 
In the present study, our aim was to investigate the 
mRNA expression of LH-RH-I receptor and LH-RH ligand 
in ocular choroidal melanoma (OCM)-1 and OCM-3 human 
UM cell lines. The presence and binding characteristics of 
the LH-RH-I receptor protein have been also examined by 
Western blot, immunocytochemistry, and ligand competi-
tion assays. In addition, we have studied the expression of 
mRNA and protein of LH-RH-I receptors in tumor tissue 
samples from nude mice xenografted with OCM-1 and 
OCM-3 cell lines.
Materials and methods
cell lines and culture conditions
OCM-1 and OCM-3 human primary UM cell lines were kindly 
provided by the Department of Biophysics and Cell Biology, 
University of Debrecen and this research had approval from 
the Institutional Ethics Committee of the University of 
Debrecen. The cells were cultured in RPMI 1640 medium 
supplemented with l-glutamine, 10% fetal bovine serum 
(FBS), and 1% penicillin/streptomycin in a humidified 
chamber in 5% CO
2
 at 37°C. Cells were subcultured every 
3 days using a standard trypsinization procedure.
animals
Athymic (nude) mice (Ncr nu/nu) were obtained from 
Charles River Laboratories (Germany). Mice were housed 
in sterile, individually ventilated cages in an air-conditioned 
(21°C±2°C), humidity-controlled room (≈50%) with a 
12/12 hour light/dark cycle. Animals were fed with auto-
claved chow and water ad libitum. All experiments were 
conducted in accordance with the institutional guidelines for 
the welfare of experimental animals and regulations of the 
European Union. The experimental protocol was approved 
by the Laboratory Animal Care and Use Committee of the 
University of Debrecen. Six million tumor cells were subcu-
taneously injected into the femoral region of the mice. Four 
weeks after the initiation of donor animals, when tumors 
had developed in donor animals, tumors were aseptically 
dissected and mechanically minced. Approximately 3 mm3 
tumor tissue was transplanted subcutaneously into nude 
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mice by a trocar needle. At the end of each experiment, 
mice were sacrificed under 3% isoflurane anesthesia using 
a small animal anesthetic device. Tumors were excised and 
weighed and necropsy was done. Tumor specimens were 
snap-frozen and stored at −70°C until further experiments.
rna isolation, reverse transcription and 
quantitative real-time polymerase chain 
reaction (rT-qPcr)
Total RNA was isolated using NucleoSpin RNA and Protein 
Purification Kit (Macherey-Nagel, Düren, Germany) 
according to the manufacturer’s instructions. RNA from 
each sample (2,000 ng) was reverse transcribed to cDNA 
using a Tetro cDNA Synthesis Kit (Bioline, London, UK) 
in a final volume of 20 µL. In order to evaluate the expres-
sion of type I LH-RH receptors and LH-RH ligand, primer 
sets were designed. Gene-specific primers for LH-RH-I 
receptor: sense 5′-GACCTTGTCTGGAAAGATCC-3′ 
(EXON 1 1,844–1,863), antisense 5′-CAGGCTGATCAC 
CACCATCA-3′ (EXON 1 1,844–1,863), for LH-RH ligand: 
sense 5′-GGCCTTATTCTACTGACTTGG-3′, antisense 
5′-TCTTCTGCCCAGTTTCCTCT-3′. Hypoxanthine phos-
phoribosyltransferase 1 (HPRT1) was used as an internal ref-
erence gene (sense 5′-GTATTCATTATAGTCAAGGGCAT
ATCC-3′, antisense 5′-AGATGGTCAAGGTCGCAAG-3′). 
mRNA levels of LH-RH-R-I, LH-RH, and HPRT1 have 
been assessed by iQ™ SYBR® Green Supermix (Bio-Rad 
Laboatories Inc, Hercules, CA, USA). Reactions were 
conducted according to the manufacturer’s protocol using 
MyiQ2 two-color real-time PCR detection system (Bio-Rad 
Laboratories Inc). All real-time amplifications were measured 
in triplicates. Results were evaluated with Bio-Rad iQ5 
software (Bio-Rad Laboatories Inc) and changes in mRNA 
levels were calculated using the 240-Ct method.
immunocytochemistry
immunoperoxidase staining
To detect LH-RH-I receptors, OCM-1 and OCM-3 cells 
were fixed in ice-cold methanol (10 minutes). Endogenous 
peroxidase activity was blocked in 3% hydrogen peroxide 
(10 minutes). Samples were permeabilized with 0.1% Triton 
X-100 and blocked with 1% bovine serum albumin (BSA) – 
1% FBS solution in 0.1% Triton X-100 (room temperature, 1 
hour). Samples were incubated with primary anti-LH-RH-R 
antibody (sc-13944 rabbit polyclonal; Santa Cruz Biotechnol-
ogy Inc, Dallas, TX, USA; 1:50) (overnight, 4°C) and EnVi-
sion Flex, horseradish peroxidase (Agilent Technologies, 
Santa Clara, CA, USA) (room temperature, 1 hour). Signals 
were detected using a ready-to-use 3,3′-diaminobenzidine 
substrate kit (Agilent Technologies). Samples were rinsed 
with tap water, dehydrated through a graded series of alcohol, 
and mounted with ProLong® Diamond Antifade Mountant 
(Molecular Probes, Eugene, OR, USA).
Immunofluorescent labeling
To investigate LH-RH-I receptors, OCM-1 and OCM-3 cells 
were fixed in 4% paraformaldehyde at room temperature for 
10 minutes, permeabilized with 0.1% Triton X-100 at room 
temperature for 1 hour, and blocked with 5% BSA in 0.1% 
Triton X-100 solution at room temperature for 1 hour. Samples 
were incubated with primary anti-LH-RH-R antibody (sc-13944 
rabbit polyclonal; Santa Cruz Biotechnology Inc; 1:50) (over-
night, 4°C) and anti-rabbit fluorescein isothiocyanate second-
ary antibody (Thermo Fisher Scientific, Waltham, MA, USA; 
1:1,000). Samples were rinsed and mounted with ProLong® 
Diamond Antifade Mountant with DAPI (Molecular Probes). 
Staining was evaluated using an Olympus FV-1000 confocal 
microscope (Olympus Corporation, Tokyo, Japan).
Western blot
Total protein was isolated using NucleoSpin RNA and 
Protein Purification Kit (Macherey-Nagel) according to the 
manufacturer’s instructions. Total protein amount of the 
supernatant was determined by a Nanodrop ND-1000 UV-
Vis Spectrophotometer (ThermoFisher Scientific). Equal 
amounts of proteins (20 µg) were separated in 10% sodium 
dodecyl sulfate-polyacrylamide gels and then transferred 
to polyvinylidene fluoride membrane using standard pro-
cedures.28 Upon blocking with 5% BSA, membranes were 
incubated with primary antibodies (overnight, 4°C): anti-
LH-RH-R, 1:200 dilution (sc-13944 rabbit polyclonal; Santa 
Cruz Biotechnology Inc), anti-GAPDH, 1:1,000 dilution 
(D16H11 rabbit monoclonal; Cell Signaling Technology, 
Danvers, MA, USA). Proteins were detected with anti-rabbit 
horseradish peroxidase conjugated antibody (mouse sc-2357; 
Santa Cruz Biotechnology Inc) and Luminata Forte Western 
horseradish peroxidase Substrate (Merck Millipore, Billerica, 
MA, USA). The protein bands were quantified using Image 
Lab software (Bio-Rad Laboratories Inc).
Preparation of membranes and 
radioligand binding studies
Preparation of membranes for receptor studies was per-
formed as described previously.23,24,27 Receptor binding 
was characterized using sensitive in vitro ligand competi-
tion assay based on binding of [125I][D-Trp6]LH-RH as 
radioligand to membrane homogenates.23,24,27 The binding 
characteristics of receptors for LH-RH-I were determined 
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in the membrane fraction of OCM-1 and OCM-3 human 
UM cell lines (1.8–2.4×108 cells each) and in OCM-1 and 
OCM-3 tumors grown in nude mice. Radioiodinated deriva-
tives of [D-Trp6]LH-RH were prepared by the chloramine-T 
method and purified by reverse-phase high-performance 
liquid chromatography as described.23,24 This radioligand 
has been well-characterized previously and showed high 
affinity binding to LH-RH-I receptors expressed in human 
and rat pituitaries and human breast, prostate, and other 
cancers.19,20,23,24,29 In brief, membrane homogenates containing 
50–160 µg protein were incubated in duplicate or triplicate 
with 60–80,000 cpm [125I][D-Trp6]LH-RH and increasing 
concentrations (10−12–10−6 M) of nonradioactive peptides as 
competitors in a total volume of 150 µL of binding buffer. 
At the end of incubation, 125 µL aliquots of the suspension 
were transferred onto the top of 1 mL of ice-cold binding 
buffer containing 1.5% BSA in siliconized polypropylene 
microcentrifuge tubes (Sigma-Aldrich Co, St Louis, MO, 
USA). The tubes were centrifuged at 12,000× g for 3 minutes 
at 4°C. Supernatants were aspirated and the bottoms of the 
tubes containing the pellet were cut off and counted in a 
gamma counter. Protein concentration was determined by the 
method of Bradford using a protein assay kit (Bio-Rad Labo-
ratories Inc). The LIGAND-PC computerized curve-fitting 
program of Munson and Rodbard was used to determine the 
type of receptor binding, dissociation constant (K
d
), and the 
maximal binding capacity of the receptors (B
max
).23,24,27
statistical analysis
Correlation analysis was carried out between the expression 
of mRNA for LH-RH-I receptor and expression of mRNA for 
LH-RH ligand with the use of GraphPad Prism 7 (GraphPad 
Software Inc, La Jolla, CA, USA). The two data sets were 
evaluated using Kolmogorov–Smirnov normality test, and 
then Pearson correlation analysis was performed. 
Results
expression of type i lh-rh receptors in 
human UM cell lines in vitro
mRNA expression for LH-RH-I receptors was analyzed in 
OCM-1 and OCM-3 cell lines by RT-qPCR. LH-RH-I recep-
tors were detected in both these human UM cell lines, with a 
slightly higher expression of LH-RH-I receptor observed in 
OCM-3 cells (Figure 1A). Western blot analysis confirmed 
the presence of LH-RH-I receptors in OCM-1 and OCM-3 
cells and revealed a signal corresponding to a protein 
of ~68 kDa, which is the molecular mass of the LH-RH-I 
receptor reported earlier30 (Figure 2). In accordance with the 
receptor mRNA data, a slightly higher protein expression of 
LH-RH-I receptors was observed in OCM-3 cells by Western 
blot and immunocytochemical analysis (Figure 3). 
expression of type i lh-rh receptors 
in vivo in tumor xenograft models
The mRNA expression for receptors for LH-RH-I in OCM-1 
and OCM-3 tumors grown in nude mice was analyzed by 
RT-qPCR. mRNA for LH-RH-I receptors could be detected 
in all tumor xenografts (Figure 1A). In accordance with our 
in vitro results, the level of the LH-RH-I receptor tran-
script in our OCM-3 model was considerably higher than 
in the OCM-1 tumor samples in vivo. Western blot analysis 
also confirmed the presence of LH-RH-I receptor protein in 
OCM-1 and OCM-3 tumor tissues. Similar to our in vitro 
finding, higher expression level of LH-RH-I receptor was 
found in OCM-3 tumor xenografts, also detected by Western 
blots (Figure 2). 
Figure 1 rT-qPcr analysis of the expression of mrna for lh-rh-i receptor (A) and lh-rh ligand (B) in human uveal melanoma cell lines: 1) OcM-1, 2) OcM-3, 
3) xenografted OcM-1, 4) xenografted OcM-3, 5) positive control, human pituitary. Y-axis represents fold change in gene expression, normalized to HPRT1 gene. Data 
represent mean values ± se (n=3).
Abbreviations: lh-rh-i, luteinizing hormone-releasing hormone type i; rT-qPcr, reverse transcription-quantitative polymerase chain reaction; OcM, ocular choroidal 
melanoma; se, standard error.
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radioligand binding studies
The presence of specific LH-RH binding sites and charac-
teristics of binding of [125I][D-Trp6]LH-RH to membrane 
receptors on OCM-1 and OCM-3 human UM models were 
determined using ligand competition assays. Analyses of 
the typical displacement of radiolabeled [D-Trp6]LH-RH by 
the same unlabeled peptide revealed that the one-site model 
provided the best fit, indicating the presence of one class of 
high affinity LH-RH-I receptors in crude membranes derived 
from human UM cells. In cell membranes of OCM-1 and 
OCM-3 human UM cell lines, ligand competition studies 
also revealed a single class of high affinity binding sites for 
LH-RH-I with mean dissociation constants (K
d
) of 4.11±0.3 
and 4.26±0.6 nM, respectively (Table 1). The concentration 
of LH-RH-I receptors was 233.6±21.7 fmol/mg membrane 
protein in OCM-1 cells while OCM-3 cells showed a mark-
edly higher receptor level (1,029.1±68.5 fmol/mg membrane 
protein) (Table 1). Receptors for LH-RH-I were also found 
in membranes of OCM-1 and OCM-3 tumor tissue samples. 
Radiolabeled [D-Trp6]LH-RH was bound to a single class 
of specific, high affinity binding sites in both human UM 
models investigated. Mean K
d
 values were 5.85±0.7 nM 
for OCM-1 tumors and 6.18±0.8 nM for OCM-3 tumors 
(Table 2). Mean B
max
 values were 267.3±38.5 fmol/mg 
membrane protein in OCM-1 tumors and about 2.7 times 
higher (713.0±29.4 fmol/mg membrane protein) for OCM-3 
xenografts (Table 2). Biochemical parameters essential to 
establish the identity of specific binding sites were also 
determined. Thus, the binding of [125I][D-Trp6]LH-RH was 
found to be reversible, time- and temperature-dependent, and 
linear with protein concentration in human UM samples. The 
specificity of LH-RH binding was demonstrated by competi-
tive binding experiments using several peptides structurally 
related or unrelated to LH-RH. The binding of radiolabeled 
[D-Trp6]LH-RH was completely displaced by increasing 
concentrations (10−12–10−6 M) of LH-RH agonist buserelin 
and LH-RH antagonist cetrorelix (data not shown). 
expression of lh-rh mrna in human 
UM cell lines and tumor xenografts
In addition to LH-RH receptor studies, the expression of 
LH-RH ligand in OCM-1 and OCM-3 models was also 
Figure 2 Western blot analysis of lh-rh-i receptor in human uveal melanoma cell 
lines: 1) OcM-1, 2) OcM-3, 3) xenografted OcM-1, 4) xenografted OcM-3. The 
intensity of signals was quantified by densitometric scanning and normalized to that 
of gaPDh. each value is the average of two technical replicates.
Abbreviations: lh-rh-i, luteinizing hormone-releasing hormone type i; OcM, 
ocular choroidal melanoma.
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Figure 3 immunocytochemical analysis of lh-rh-i receptor in OcM-1 and OcM-3 cell lines. (A) immunoperoxidase staining: 1) OcM-1, 2) OcM-3, 3) no antibody control. 
Inset: positive control, human pituitary, DAB (brown); magnification 20×. (B) Immunofluorescent labeling: 1) OCM-1, 2) OCM-3, 3) no antibody control, FITC (green); 
magnification 60×. 
Abbreviations: LH-RH-I, luteinizing hormone-releasing hormone type I; OCM, ocular choroidal melanoma; FITC, fluorescein isothiocyanate; DAB, 3,3′-diaminobenzidine.
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investigated by RT-qPCR. Presence of mRNA for LH-RH 
ligand was detected in both cell lines and tumors grown in 
nude mice (Figure 1B). Although the expression of LH-RH-R 
was markedly higher in the OCM-3 UM model, the mRNA 
expression of LH-RH ligand was only slightly higher in the 
OCM-1 UM cell line (Figure 1B). 
correlation between type i lh-rh 
receptor and lh-rh ligand
According to our statistical analysis, there is a significant 
correlation between the expression of LH-RH-I receptor 
and LH-RH ligand in OCM-1 cell line and in OCM-1 tumor 
xenografts in vivo (Pearson r=0.8380; p=0.0373, CI =0.95%). 
Moreover, we also observed a significant correlation between 
the expressions of LH-RH-R-I and LH-RH ligand in OCM-3 
cells and OCM-3 tumors grown in nude mice (Pearson 
r=0.9878; p=0.0002, CI =0.95%) (Figure 4).
Discussion
UM is the most common primary intraocular cancer of the 
eye. Risk factors for the development of UM are, among 
others, Caucasian ethnicity, light eye color, ocular melano-
cytosis and dysplastic naevus syndrome.31 Therefore, a better 
understanding of the molecular background of UM and the 
development of new therapeutic approaches are urgently 
needed.
A growing body of evidence shows that the LH-RH recep-
tor can serve as a potential therapeutic target.17–24,29 LH-RH 
regulates the reproductive system through a specific GPCR 
in pituitary gonadotropes.19,20,32 The presence of various 
forms of LH-RH is connected with the existence of LH-RH 
receptor subtypes. In vertebrates, three subtypes of LH-RH 
receptors have been identified.32–37 Principally, type I recep-
tors are localized in the pituitary and mediate the regulation 
of gonadotropin secretion.32–36 Type II LH-RH receptors 
are well preserved in many vertebrates.32,34 In humans, 
type II receptors have become nonfunctional.32,34 Their func-
tion – being the target for LH-RH-II – has been taken up by 
type I receptors.32,34 However, LH-RH-II activates type I 
receptors differently than LH-RH-I.35 Interestingly, it has 
been shown that type II LH-RH receptors might play a role 
in tumor cell growth.33 Type III LH-RH receptors seem to 
be related to type II receptors; thus, they may have common 
genetic roots.34
Receptors for LH-RH-I are mainly localized in the pitu-
itary and LH-RH ligand in the hypothalamus. However, there 
are several studies showing LH-RH and LH-RH-I receptor 
expression in extrapituitary reproductive tissues: not only in 
the ovary, placenta, testis, and prostate, but also in nonre-
productive organs including the liver, heart, kidney, skeletal 
muscle, blood mononuclear cells, and incisor teeth.20,21,38–44 
In UM research, cell lines have been widely used in order to 
identify and characterize the disease in vitro.45 In the present 
study, our aim was to investigate the mRNA expression for 
LH-RH ligand and LH-RH-I receptors in OCM-1 and OCM-3 
human UM cell lines. Those cultures were derived from 
primary UMs.46 The presence and binding characteristics of 
LH-RH-I receptor protein were also determined by Western 
blot, immunocytochemistry, and ligand competition assays. 
Furthermore, we demonstrated the expression of LH-RH-I 
receptors at mRNA as well as protein levels in OCM-1 and 
OCM-3 models transplanted into nude mice. 
The expression of LH-RH-I receptors lends support to the 
therapeutic use of LH-RH analogs linked to cytotoxic drugs 
in human UM as well as many other hormone-dependent 
tumors.19–23,47,48 Targeted tumor therapy reduces peripheral 
toxicity and adverse reactions compared to systemic che-
motherapeutic agents, and increases selective damage to 
cancer cells.17,19–22,47,48 For instance, AN-152 (AEZS-108), 
a cytotoxic LH-RH analog widely used in targeted therapy, 
consists of doxorubicin linked covalently to LH-RH agonist 
[D-Lys6]LH-RH. AN-152 binds with high affinity to LH-RH 
receptors on the membrane of various cancer cells.19–23,30,47–50 
Moreover, therapy with cytotoxic LH-RH analogs does not 
Table 1 Binding characteristics of lh-rh-i receptors in OcM-1 
and OcM-3 human uveal melanoma cells
Cell line KD (nM) Bmax 
(fmol/mg protein)
OcM-1 4.11±0.3 233.6±21.7 
OcM-3 4.26±0.6 1,029.1±68.5 
Notes: Binding charac teristics were obtained from ligand competition assays 
(each done in triplicate). Based on the binding of radiolabeled [D-Trp6]lh-rh to 
membrane homogenates. all values represent mean ± se.
Abbreviations: lh-rh-i, luteinizing hormone-releasing hormone type i; OcM, 
ocular choroidal melanoma; se, standard error; KD, dissociation constant; Bmax, 
maximal binding capacity.
Table 2 Binding characteristics of lh-rh-i receptors in OcM-1 
and OcM-3 human uveal melanoma xenografted into nude mice
Cell line KD (nM) Bmax  
(fmol/mg protein)
OcM-1 5.85±0.7 267.3±38.5
OcM-3 6.18±0.8 713.0±29.4
Notes: Binding charac teristics were obtained from ligand competition assays 
(each done in triplicate). Based on the binding of radiolabeled [D-Trp6]lh-rh to 
membrane homogenates. all values represent mean ± se.
Abbreviations: lh-rh-i, luteinizing hormone-releasing hormone type i; OcM, 
ocular choroidal melanoma; se, standard error; KD, dissociation constant; Bmax, 
maximal binding capacity.
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expression of lh-rh-i receptor and lh-rh ligand
inflict permanent damage to pituitary function and does not 
induce any cardiotoxicity.49,51,52 AN-152 has been tested in 
Phase I/II trials in castration-resistant prostate cancer and 
in Phase II and III clinical trials in endometrial and ovarian 
cancers.47,49,53,54 Modern LH-RH antagonists such as degarelix 
could be also tried.
In this study, we provide evidence for the existence 
of LH-RH-I receptors in two human UM cell lines and 
demonstrate that OCM-3 cells express LH-RH-I receptors 
at a higher level than OCM-1 cells. The same expression 
pattern has been observed in our in vivo models. Moreover, 
a remarkable expression of mRNA for LH-RH ligand was 
detected in both cell lines and cancer tissues grown in nude 
mice. Significant correlation was found between the LH-
RH-I receptor and LH-RH ligand expression in OCM-1 and 
OCM-3 cell lines. The presence of LH-RH-I receptor protein 
was confirmed in both cell lines cultured in vitro and tissue 
samples from nude mice using Western blot. In addition, 
using ligand competition assay we examined the binding of 
[125I][D-Trp6]LH-RH to membrane preparations of OCM-1 
and OCM-3 human UM models. In both human UM models 
investigated, specific high affinity LH-RH-I receptors were 
found. The expression of LH-RH ligand and co-expression 
of LH-RH-I receptors support the idea that they might play 
a role in an autocrine and/or paracrine regulatory system 
in human UM; however, further studies are required to 
confirm this.
Our results provide further support to the hypothesis that 
locally produced LH-RH may participate in the regulation 
of tumor growth.19,20,25,50,55,56
Conclusion
In this study we demonstrated the expression of LH-RH-I 
receptor as a potential therapeutic target and LH-RH ligand in 
two human UM cell lines and tumor xenografts grown in nude 
mice. Our findings support the development of new thera-
peutic approaches based on LH-RH antagonists or cytotoxic 
analogs of LH-RH targeting LH-RH receptors in UM.
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